Biotech companies directory 2026

    Biotech Companies in Turkey

    Turkish biotechnology grew out of large chemistry-based pharmaceutical houses that bolted on vaccine, hormone and biosimilar suites, not out of a venture-backed antibody cluster sitting beside a single campus.

    Abdi İbrahim is the domestic volume leader and has spent a decade putting biologics and sterile capacity next to its classic branded-generic engine. DEVA, listed and export-heavy, talks biosimilars the way it once talked oral solids. Koçak Farma is the name that appears on pandemic vaccine files — both its own inactivated candidate and filling work on TURKOVAC batches — which is as close as Turkey has to a VACSERA-style national antigen story. Nobel İlaç, Atabay, Vem, Ali Raif and Biofarma add further sterile and specialty plants across Istanbul, Kocaeli and Tekirdağ. Eczacıbaşı-Monrol occupies a different niche, radiopharmaceuticals, which hospital nuclear-medicine departments treat as a biologic-adjacent supply problem. TİTCK registers every product and inspects every suite. TÜBİTAK MAM and TÜSEB fund and host the public-lab side; Erciyes University’s vaccine centre showed during COVID that an academic GMP unit can matter. SGK reimbursement, not a venture exit, is what makes a Turkish biosimilar real. The directory therefore lists manufacturers, public labs, the agency and a few originator affiliates so a partnering team can see who has steel, who has a file and who pays.

    Updated September 2026 · Turkish Medicines and Medical Devices Agency (TİTCK) — registered biological products and licensed establishments as of September 2026 · 16 named accounts

    Request a proposal for TurkeyBrowse the 16 companies

    1

    National medicines agency (TİTCK) that registers biologics, vaccines and biosimilars

    ~99%

    Residents on SGK general cover — the reimbursement door that makes a biosimilar launch real

    2

    Public science counterparts most often named on vaccine files: TÜBİTAK MAM and TÜSEB

    2020–22

    Years when Koçak, Erciyes and TÜSEB put Turkish-made COVID antigens into regulated studies

    Named accounts

    Top biotechnology companies in Turkey

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Turkish Medicines and Medical Devices Agency (TİTCK) — registered biological products and licensed establishments (as of 2026-09-04).
    #CompanyHQ
    01Abdi İbrahimIstanbul
    02DEVA HoldingIstanbul
    03Koçak FarmaIstanbul
    04Nobel İlaçIstanbul
    05Atabay İlaçIstanbul
    06Vem İlaçIstanbul
    07Ali Raif İlaçIstanbul
    08Biofarma İlaçIstanbul
    09Eczacıbaşı-MonrolIstanbul
    10Hasbiotech İlaçIstanbul
    11Roche Turkey and Novo Nordisk TurkeyIstanbul
    12TÜBİTAK Marmara Research Center (MAM)Gebze
    13TÜSEB (Health Institutes of Turkey)Istanbul
    14Erciyes University — vaccine research and GCP centreKayseri
    15Turkish Medicines and Medical Devices Agency (TİTCK)Ankara
    16Social Security Institution (SGK) — pharmaceuticalsAnkara

    Primary research

    These are the biotech and innovation accounts we track in Turkey

    Partnering, licensing or launching a biologic in Turkey? BioNixus runs KOL, payer and regulator interviews plus hospital-level demand sizing. Proposal within 48 hours.

    Planning research in Turkey?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in Turkey (2026)

    How the market is structured

    How Turkish manufacturers turn chemistry houses into biologics plants

    The path is incremental. A listed or family company already selling SGK-reimbursed tablets adds a sterile hall, licences a biosimilar or a vaccine technology, and files a TİTCK biologic dossier. Drug-substance capability exists in places — hormones, some antigens, radiopharmacy — but many “biologics” on the Turkish market are still filled or packaged from imported bulk. TİTCK’s biosimilar and biological-product guidance sits on top of ordinary GMP and pricing rules; a reference product and a comparability package are expected, and a Turkish marketing authorisation holder is mandatory. Once registered, the commercial question is SGK’s Health Implementation Communiqué: if the molecule is missing from the communiqué and from ward protocols, the biosimilar stays on the shelf, however elegant the plant tour. Private chains — Acıbadem, MLP Care, Memorial — adopt some originator specialties faster than Ministry city hospitals, which is why originator affiliates remain in this table. Export to the Balkans, the Caucasus, the Gulf and North Africa pays for the next suite. Academic engines at Hacettepe, Istanbul University, Koç and Erciyes supply investigators and, occasionally, a platform; they do not replace TİTCK or SGK. A foreign developer that wants a Turkish manufacturing partner is therefore shopping among chemistry houses with biologics ambitions, not among twenty Genentech copies.

    Local

    Istanbul- and Marmara-region chemistry houses that added vaccine, hormone, radiopharma or biosimilar suites — Abdi İbrahim, DEVA, Koçak, Nobel and their peers.

    • Abdi İbrahim
    • DEVA Holding
    • Koçak Farma
    • Nobel İlaç
    • Atabay İlaç
    • Vem İlaç
    • Ali Raif İlaç
    • Biofarma İlaç
    • Eczacıbaşı-Monrol
    • Hasbiotech İlaç

    Multinational

    Originator affiliates that still set the switching and protocol baseline for insulin, oncology and immunology biologics inside SGK and private chains.

    • Roche Turkey and Novo Nordisk Turkey

    Regional

    Turkish groups themselves act as the regional manufacturers for the Balkans and the Caucasus; incoming Levant or Gulf plants are rare on this file.

    Incubators, CDMOs & partners

    TİTCK, SGK, TÜBİTAK MAM, TÜSEB and the Erciyes vaccine centre — the agency, the payer and the public laboratories.

    • TÜBİTAK Marmara Research Center (MAM)
    • TÜSEB (Health Institutes of Turkey)
    • Erciyes University — vaccine research and GCP centre
    • Turkish Medicines and Medical Devices Agency (TİTCK)
    • Social Security Institution (SGK) — pharmaceuticals

    What is moving

    What is moving biotechnology in Turkey

    SGK reimbursement as the real launch gate

    A TİTCK licence without a SUT code leaves a biosimilar on the shelf; hospital protocols and city-hospital tenders then decide monthly volume.

    Vaccine files that outlived the pandemic

    Koçak, Erciyes and TÜSEB built antigen and filling know-how that the Ministry still treats as strategic, even after COVID demand fell.

    Export cash for the next sterile hall

    Balkan, Caucasian, Gulf and North African tenders pay for suites that SGK prices alone would not justify.

    Private chains as early specialty adopters

    Acıbadem, Liv and Memorial take originator biologics and some biosimilars faster than Ministry city hospitals, creating a second, smaller but faster door.

    BioNixus fieldwork

    How BioNixus studies biotechnology companies in Turkey

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Turkey:
    • Biosimilar switching interviews with hospital pharmacists at Ministry city hospitals and at Acıbadem and MLP Care sites in Istanbul and Ankara.
    • Plant-capability discussions in Istanbul, Gebze and Kayseri that record which vaccine and biosimilar suites are inspected versus announced.
    • SUT and protocol-list mapping with medical directors on how a newly registered biologic actually reaches a city-hospital ward.
    • Investigator interviews at Hacettepe, Koç and Erciyes on industry versus academic biologics protocols.

    Healthcare market research in Turkey

    Questions

    Frequently Asked Questions

    Does Turkey have a VACSERA-style national vaccine company?

    Not as a single holding company. Koçak Farma, Erciyes University’s vaccine centre and TÜSEB jointly carried the highest-profile antigen files. Treat that triangle as the functional equivalent, not as one equity story.

    Who leads domestic biologics manufacturing?

    Abdi İbrahim and DEVA are the scale pharmaceutical groups adding biosimilar and sterile capacity. Koçak is the vaccine specialist. Eczacıbaşı-Monrol owns radiopharmacy. None is a pure discovery biotech.

    What does TİTCK require for a biosimilar?

    A biological-product file with comparability to a reference, Turkish GMP and a local marketing authorisation holder, then a separate SGK listing fight. There is no PIF-style joint-venture shortcut.

    Where should a plant tour go?

    Istanbul and Kocaeli/Gebze for most private suites and for TÜBİTAK MAM; Kayseri for Erciyes; Ankara for TİTCK and SGK. Tekirdağ and other Marmara towns hold additional formulation halls.

    What fieldwork does BioNixus run on Turkish biotechnology organisations?

    Hospital-pharmacist interviews in Istanbul, Ankara and Izmir on biosimilar switching; TİTCK and SGK pathway mapping; and plant-capability discussions with Abdi İbrahim, DEVA and Koçak that separate licensed files from commissioned suites.

    Does table order imply which Turkish biotech is most important?

    It does not imply rank. Entries are here because they recur in BioNixus Turkey hospital and plant work and in TİTCK and BIST records. The sort is by role — manufacturer, originator affiliate, public lab, agency, payer.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Turkey. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Turkish Medicines and Medical Devices Agency (TİTCK) — registered biological products and licensed establishments, consulted 2026-09-04. Company classification (Local / MNC / Regional / incubators, cdmos & partners) reflects ownership and role in Turkey, not size.

    • TİTCK biological-product and establishment materials
    • Company and Borsa Istanbul disclosures by Abdi İbrahim, DEVA Holding and peers; TURKOVAC / Koçak clinical-trial registry entries
    • TÜBİTAK MAM and TÜSEB public programme descriptions; SGK Health Implementation Communiqué (SUT)
    • BioNixus Turkey biologics, vaccine and hospital-pharmacy fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need biotech and biologics market data in Turkey?

    Payer appetite, biosimilar uptake, KOL sentiment and tender exposure — primary research, not desk estimates.

    Planning research in Turkey?

    Primary research, market access & HEOR. Proposals within 48 hours.